Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy

Guide for the Care and Use of Laboratory Animals: Eighth Edition

(2011) · doi:10.17226/12910 · Cited by 16,199 · see citing works

Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163 · see citing works

Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy

Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520 · see citing works

Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector

Kay, M. A., Manno, C. S., Ragni, M. V., Larson, P. J., Couto, L. B., McClelland, A., Glader, B. E., Chew, A. K., Tai, S. J., Herzog, R. W., et al. (2000) · Nature Genetics · doi:10.1038/73464 · Cited by 1,019 · see citing works

AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B

Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749 · see citing works

Institute of Laboratory Animal Resources.

Wolfle, T. L. (1995) · Cited by 620 · see citing works

Induction of Immune Tolerance to Coagulation Factor IX Antigen by In Vivo Hepatic Gene Transfer

Mingozzi, F., Liu, Y.-L., Dobrzynski, E., Kaufhold, A., Liu, J. H., Wang, Y., Arruda, V. R., High, K. A., & Herzog, R. W. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16887 · Cited by 466 · see citing works

Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver

Nathwani, A. C., Gray, J. T., Ng, C. Y., Zhou, J., Spence, Y., Waddington, S. N., Tuddenham, E. G. D., Kemball‐Cook, G., McIntosh, J., Boon‐Spijker, M., et al. (2005) · Blood · doi:10.1182/blood-2005-10-4035 · Cited by 421 · see citing works

Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors

Snyder, R. O., Miao, C., Meuse, L., Tubb, J., Donahue, B. A., Lin, H.-F., Stafford, D. W., Patel, S., Thompson, A. R., Nichols, T., et al. (1999) · Nature Medicine · doi:10.1038/4751 · Cited by 409 · see citing works

Rapid Uncoating of Vector Genomes Is the Key toEfficient Liver Transduction with Pseudotyped Adeno-Associated VirusVectors

Thomas, C. E., Storm, T. A., Huang, Z., & Kay, M. A. (2004) · Journal of Virology · doi:10.1128/jvi.78.6.3110-3122.2004 · Cited by 358 · see citing works

Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy

Mount, J. D., Herzog, R. W., Tillson, D. M., Goodman, S. A., Robinson, N., McCleland, M. L., Bellinger, D., Nichols, T. C., Arruda, V. R., Lothrop, C. D., et al. (2002) · Blood · doi:10.1182/blood.v99.8.2670 · Cited by 339 · see citing works

Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice

Scallan, C. D., Jiang, H., Liu, T., Patarroyo-White, S., Sommer, J. M., Zhou, S., Couto, L. B., & Pierce, G. F. (2006) · Blood · doi:10.1182/blood-2005-08-3229 · Cited by 271 · see citing works

Quantification of adeno-associated virus particles and empty capsids by optical density measurement

Sommer, J. Ü. M., Smith, P. H., Parthasarathy, S., Isaacs, J., Vijay, S., Kieran, J., Powell, S. K., McClelland, A., & Wright, J. F. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(02)00019-9 · Cited by 230 · see citing works

Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models

Davidoff, A. M., Gray, J. T., Ng, C. Y., Zhang, Y., Zhou, J., Spence, Y., Bakar, Y., & Nathwani, A. C. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2004.12.022 · Cited by 218 · see citing works

Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy

Grimm, D., Zhou, S., Nakai, H., Thomas, C. E., Storm, T. A., Fuess, S., Matsushita, T., Allen, J. M., Surosky, R. T., Lochrie, M. A., et al. (2003) · Blood · doi:10.1182/blood-2003-02-0495 · Cited by 208 · see citing works

Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype

Sarkar, R., Tetreault, R., Gao, G., Wang, L., Bell, P. L., Chandler, R. J., Wilson, J. M., & Kazazian, H. H. (2003) · Blood · doi:10.1182/blood-2003-08-2954 · Cited by 201 · see citing works

Mutations on the External Surfaces of Adeno-AssociatedVirus Type 2 Capsids That Affect Transduction andNeutralization

Lochrie, M. A., Tatsuno, G. P., Christie, B., McDonnell, J. W., Zhou, S., Surosky, R., Pierce, G. F., & Colosi, P. (2006) · Journal of Virology · doi:10.1128/jvi.80.2.821-834.2006 · Cited by 201 · see citing works

Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs

Jiang, H., Lillicrap, D., Patarroyo-White, S. L., Liu, T., Qian, X., Scallan, C. D., Powell, S., Keller, T., McMurray, M., Labelle, A., et al. (2006) · Blood · doi:10.1182/blood-2005-12-5115 · Cited by 200 · see citing works

Biology of AAV Serotype Vectors in Liver-Directed Gene Transfer to Nonhuman Primates

Gao, G., Lü, Y., Calcedo, R., Grant, R. L., Bell, P. L., Wang, L., Figueredo, J. M., Lock, M. W., & Wilson, J. M. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.08.017 · Cited by 170 · see citing works

Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques

Nathwani, A. C., Davidoff, A. M., Hanawa, H., Hu, Y., Hoffer, F. A., Nikanorov, A. Y., Slaughter, C. A., Ng, C. Y., Zhou, J., Lozier, J. N., et al. (2002) · Blood · doi:10.1182/blood-2002-02-0589 · Cited by 164 · see citing works

Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulation

Wright, J. F., Le, T., Prado, J., Bahr-Davidson, J., Smith, P. H., Zhen, Z., Sommer, J. M., Pierce, G. F., & Qu, G. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.02.021 · Cited by 158 · see citing works

Lack of Germline Transmission of Vector Sequences Following Systemic Administration of Recombinant AAV-2 Vector in Males

Arruda, V. R., Fields, P. A., Milner, R., Wainwright, L. M., Miguel, M. P. D., Donovan, P. J., Herzog, R. W., Nichols, T. C., Biegel, J. A., Razavi, M. K., et al. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0491 · Cited by 154 · see citing works

Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice

Jung, S., Han, I., Limaye, A., Xu, R., Gelderman, M. P., Zerfas, P. M., Kamala, T., Murray, G. J., During, M. J., Brady, R. O., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051634498 · Cited by 144 · see citing works

Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer

Dobrzynski, E., Mingozzi, F., Liu, Y.-L., Bendo, E., Cao, O., Wang, L., & Herzog, R. W. (2004) · Blood · doi:10.1182/blood-2004-03-0847 · Cited by 135 · see citing works

Human Factor IX Corrects the Bleeding Diathesis of Mice With Hemophilia B

Kung, S., Hagstrom, J. N., Cass, D. L., Tai, S. J., Lin, H.-F., Stafford, D. W., & High, K. A. (1998) · Blood · doi:10.1182/blood.v91.3.784 · Cited by 129 · see citing works

Adenovirus-Mediated Expression of Human Coagulation Factor IX in the Rhesus Macaque Is Associated With Dose-Limiting Toxicity

Lozier, J. N., Metzger, M. E., Donahue, R. E., & Morgan, R. A. (1999) · Blood · doi:10.1182/blood.v94.12.3968.424k43_3968_3975 · Cited by 118 · see citing works

Gene therapy with novel adeno‐associated virus vectors substantially diminishes atherosclerosis in a murine model of familial hypercholesterolemia

Lebherz, C., Gao, G., Louboutin, J., Millar, J. S., Rader, D. J., & Wilson, J. M. (2004) · The Journal of Gene Medicine · doi:10.1002/jgm.554 · Cited by 98 · see citing works

Administration-route and gender-independent long-term therapeutic correction of phenylketonuria (PKU) in a mouse model by recombinant adeno-associated virus 8 pseudotyped vector-mediated gene transfer

Ding, Z., Georgiev, P., & Thöny, B. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302684 · Cited by 85 · see citing works

Efficient hepatic delivery and expression from a recombinant adeno-associated virus 8 pseudotyped alpha1-antitrypsin vector.

Conlon, T., Cossette, T. L., Erger, K. E., Choi, Y.-K., Clarke, T., Scott-Jorgensen, M., Song, S.-H., Campbell-Thompson, M., Crawford, J., & Flotte, T. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.05.016 · Cited by 60 · see citing works

Delivery of glucose-6-phosphatase in a canine model for glycogen storage disease, type Ia, with adeno-associated virus (AAV) vectors

Beaty, R. M., Jackson, M., Peterson, D., Bird, A., Brown, T. T., Benjamin, D. K., Juopperi, T. A., Kishnani, P. S., Boney, A., Chen, Y.-T., et al. (2002) · Gene Therapy · doi:10.1038/sj.gt.3301728 · Cited by 54 · see citing works

The Rhesus Macaque as an Animal Model for Hemophilia B Gene Therapy

Lozier, J. N., Metzger, M. E., Donahue, R. E., & Morgan, R. A. (1999) · Blood · doi:10.1182/blood.v93.6.1875.406k16_1875_1881 · Cited by 32 · see citing works

Local Delivery of a Viral Vector Mitigates Neutralization by Antiviral Antibodies and Results in Efficient Transduction of Rabbit Liver

Hodges, B. L., Taylor, K. M., Chu, Q., Scull, S. E., Serriello, R. G., Anderson, S. C., Wang, F., & Scheule, R. K. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.06.475 · Cited by 20 · see citing works

De novo use of sirolimus in immunosuppression regimens in kidney and kidney-pancreas transplantation at the University of California, San Francisco

Vincenti, F. G., & Stock, P. G. (2003) · Transplantation Proceedings · doi:10.1016/s0041-1345(03)00237-9 · Cited by 18 · see citing works

AAV-mediated gene therapy for hemophilia.

Couto, L. B., & Pierce, G. F. (2003) · PubMed · Cited by 12 · see citing works

Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors

Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970 · see citing works

Immune responses to AAV vectors: overcoming barriers to successful gene therapy

Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955 · see citing works

Emerging issues in AAV-mediated in vivo gene therapy

Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881 · see citing works

Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges

Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893 · see citing works

AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer

Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641 · see citing works

Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates

Gray, S. J., Matagne, V., Bachaboina, L., Yadav, S., Ojeda, S. R., & Samulski, R. J. (2011) · Molecular Therapy · doi:10.1038/mt.2011.72 · Cited by 501 · see citing works

Selection and evaluation of clinically relevant AAV variants in a xenograft liver model

Lisowski, L., Dane, A. P., Chu, K., Zhang, Y., Cunningham, S. C., Wilson, E. M., Nygaard, S., Grompe, M., Alexander, I. E., & Kay, M. A. (2014) · Nature · doi:10.1038/nature12875 · Cited by 450 · see citing works

Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial

Gaudet, D., Méthot, J., Déry, S., Brisson, D., Essiembre, C., Tremblay, G., Tremblay, K., de Wal, J., Twisk, J., van den Bulk, N., et al. (2013) · Gene Therapy · doi:10.1038/gt.2012.43 · Cited by 404 · see citing works

Human Immune Responses to Adeno-Associated Virus (AAV) Vectors

Ronzitti, G., Gross, D.-A., & Mingozzi, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00670 · Cited by 357 · see citing works

Overcoming Preexisting Humoral Immunity to AAV Using Capsid Decoys

Mingozzi, F., Anguela, X. M., Pavani, G., Chen, Y., Davidson, R. J., Hui, D. J., Yazicioglu, M., Elkouby, L., Hinderer, C. J., Faella, A., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005795 · Cited by 355 · see citing works

Adeno-Associated Virus Antibody Profiles in Newborns, Children, and Adolescents

Calcedo, R., Morizono, H., Wang, L., McCarter, R., He, J., Jones, D., Batshaw, M. L., & Wilson, J. M. (2011) · Clinical and Vaccine Immunology · doi:10.1128/cvi.05107-11 · Cited by 345 · see citing works

IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies

Leborgne, C., Barbon, E., Alexander, J. M., Hanby, H., Delignat, S., Cohen, D. M., Collaud, F., Muraleetharan, S., Lupo, D., Silverberg, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0911-7 · Cited by 336 · see citing works

AAV-1–mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells

Mingozzi, F., Meulenberg, J. J., Hui, D. J., Basner-Tschakarjan, E., Hasbrouck, N. C., Edmonson, S. A., Hutnick, N. A., Betts, M. R., Kastelein, J. J., Stroes, E. S., et al. (2009) · Blood · doi:10.1182/blood-2008-07-167510 · Cited by 295 · see citing works

Retinal AAV8-RS1 Gene Therapy for X-Linked Retinoschisis: Initial Findings from a Phase I/IIa Trial by Intravitreal Delivery

Cukras, C., Wiley, H. E., Jeffrey, B. G., Sen, H. N., Turriff, A., Zeng, Y., Vijayasarathy, C., Marangoni, D., Ziccardi, L., Kjellstrom, S., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.025 · Cited by 268 · see citing works

Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration

Meliani, A., Boisgerault, F., Hardet, R., Marmier, S., Collaud, F., Ronzitti, G., Leborgne, C., Costa Verdera, H., Simon Sola, M., Charles, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06621-3 · Cited by 265 · see citing works

Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver

Mingozzi, F., Hasbrouck, N. C., Basner-Tschakarjan, E., Edmonson, S. A., Hui, D. J., Sabatino, D. E., Zhou, S., Wright, J. F., Jiang, H., Pierce, G. F., et al. (2007) · Blood · doi:10.1182/blood-2007-03-080093 · Cited by 254 · see citing works

Immune responses to retinal gene therapy using adeno-associated viral vectors – implications for treatment success and safety

Bucher, K., Rodríguez-Bocanegra, E., Dauletbekov, D., & Fischer, M. D. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100915 · Cited by 242 · see citing works

Humoral immune response to AAV

Calcedo, R., & Wilson, J. M. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00341 · Cited by 243 · see citing works

Unraveling the complex story of immune responses to AAV vectors trial after trial.

Vandamme, C., Adjali, O., & Mingozzi, F. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.150 · Cited by 234 · see citing works

Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy

Haurigot, V., Marcó, S., Ribera, A., Garcia, M., Ruzo, A., Villacampa, P., Ayuso, E., Añor, S., Andaluz, A., Pineda, M., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66778 · Cited by 215 · see citing works

Overcoming innate immune barriers that impede AAV gene therapy vectors

Muhuri, M., Maeda, Y., Ma, H., Ram, S., Fitzgerald, K. A., Tai, P. W. L., & Gao, G. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143780 · Cited by 212 · see citing works

Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia

Li, C., Narkbunnam, N., Samulski, R. J., Asokan, A., Hu, G., Jacobson, L. J., Manco-Johnson, M. J., Monahan, P. E., & The Joint Outcome Study Investigators (2012) · Gene Therapy · doi:10.1038/gt.2011.90 · Cited by 225 · see citing works

Impact of Pre-Existing Immunity on Gene Transfer to Nonhuman Primate Liver with Adeno-Associated Virus 8 Vectors

Wang, L., Calcedo, R., Bell, P., Lin, J., Grant, R. L., Siegel, D. L., & Wilson, J. M. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.031 · Cited by 212 · see citing works

Overcoming the Host Immune Response to Adeno-Associated Virus Gene Delivery Vectors: The Race Between Clearance, Tolerance, Neutralization, and Escape

Mingozzi, F., & High, K. A. (2017) · Annual Review of Virology · doi:10.1146/annurev-virology-101416-041936 · Cited by 206 · see citing works

A 10 Patient Case Report on the Impact of Plasmapheresis Upon Neutralizing Factors Against Adeno-associated Virus (AAV) Types 1, 2, 6, and 8

Monteilhet, V., Saheb, S., Boutin, S., Leborgne, C., Veron, P., Montus, M.-F., Moullier, P., Benveniste, O., & Masurier, C. (2011) · Molecular Therapy · doi:10.1038/mt.2011.108 · Cited by 206 · see citing works

Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction

Fitzpatrick, Z., Leborgne, C., Barbon, E., Masat, E., Ronzitti, G., van Wittenberghe, L., Vignaud, A., Collaud, F., Charles, S., Simon Sola, M., et al. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.02.003 · Cited by 192 · see citing works

Multifunctional CRISPR-Cas9 with Engineered Immunosilenced Human T Cell Epitopes

Ferdosi, S. R., Ewaisha, R., Moghadam, F., Krishna, S., Park, J. G., Ebrahimkhani, M. R., Kiani, S., & Anderson, K. S. (2019) · Nature Communications · doi:10.1038/s41467-019-09693-x · Cited by 204 · see citing works

BAX 335 hemophilia b gene therapy clinical trial results: Potential impact of CpG sequences on gene expression

Konkle, B. A., Walsh, C. E., Escobar, M. A., Josephson, N. C., Young, G., von Drygalski, A., McPhee, S. W. J., Samulski, R. J., Bilic, I., de la Rosa, M., et al. (2021) · Blood · doi:10.1182/blood.2019004625 · Cited by 189 · see citing works

Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors

Pien, G. C., Basner-Tschakarjan, E., Hui, D. J., Mentlik, A. N., Finn, J. D., Hasbrouck, N. C., Zhou, S., Murphy, S. L., Maus, M. V., Mingozzi, F., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36891 · Cited by 192 · see citing works

Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery

Nidetz, N. F., McGee, M. C., Tse, L. V., Li, C., Cong, L., Li, Y., & Huang, W. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107453 · Cited by 174 · see citing works

rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis

Shen, W., Liu, S., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1001263 · Cited by 173 · see citing works

Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates

Kotterman, M. A., Yin, L., Strazzeri, J. M., Flannery, J. G., Merigan, W. H., & Schaffer, D. V. (2015) · Gene Therapy · doi:10.1038/gt.2014.115 · Cited by 169 · see citing works

Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models

Rapti, K., Louis-Jeune, V., Kohlbrenner, E., Ishikawa, K., Ladage, D., Zolotukhin, S., Hajjar, R. J., & Weber, T. (2012) · Molecular Therapy · doi:10.1038/mt.2011.177 · Cited by 170 · see citing works

Naturally enveloped AAV vectors for shielding neutralizing antibodies and robust gene delivery in vivo

György, B., Fitzpatrick, Z., Crommentuijn, M. H. W., Mu, D., & Maguire, C. A. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.05.032 · Cited by 153 · see citing works

Achieving the Promise of Therapeutic Extracellular Vesicles: The Devil is in Details of Therapeutic Loading

Sutaria, D. S., Badawi, M., Phelps, M. A., & Schmittgen, T. D. (2017) · Pharmaceutical Research · doi:10.1007/s11095-017-2123-5 · Cited by 140 · see citing works

Adeno-Associated Virus Gene Therapy for Liver Disease

Kattenhorn, L. M., Tipper, C. H., Stoica, L., Geraghty, D. S., Wright, T. L., Clark, K. R., & Wadsworth, S. C. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.160 · Cited by 138 · see citing works

Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue

Mingozzi, F., Chen, Y., Edmonson, S. C., Zhou, S., Thurlings, R. M., Tak, P. P., High, K. A., & Vervoordeldonk, M. J. (2013) · Gene Therapy · doi:10.1038/gt.2012.55 · Cited by 138 · see citing works

Immune Responses to Intramuscular Administration of Alipogene Tiparvovec (AAV1-LPL ^S447X ) in a Phase II Clinical Trial of Lipoprotein Lipase Deficiency Gene Therapy

Ferreira, V., Twisk, J., Kwikkers, K., Aronica, E., Brisson, D., Methot, J., Petry, H., & Gaudet, D. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.169 · Cited by 137 · see citing works

The Pleiotropic Effects of Natural AAV Infections on Liver-directed Gene Transfer in Macaques

Wang, L., Calcedo, R., Wang, H., Bell, P., Grant, R., Vandenberghe, L. H., Sanmiguel, J., Morizono, H., Batshaw, M. L., & Wilson, J. M. (2010) · Molecular Therapy · doi:10.1038/mt.2009.245 · Cited by 130 · see citing works

Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors

Meliani, A., Boisgerault, F., Fitzpatrick, Z., Marmier, S., Leborgne, C., Collaud, F., Simon Sola, M., Charles, S., Ronzitti, G., Vignaud, A., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017010181 · Cited by 127 · see citing works

Therapeutic hFIX activity achieved after single AAV5-hFIX treatment in hemophilia b patients and NHPs with pre-existing anti-AAV5 NABs

Majowicz, A., Nijmeijer, B., Lampen, M. H., Spronck, L., de Haan, M., Petry, H., van Deventer, S. J., Meyer, C., Tangelder, M., & Ferreira, V. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.05.009 · Cited by 126 · see citing works

Testing preexisting antibodies prior to AAV gene transfer therapy: rationale, lessons and future considerations

Mendell, J. R., Connolly, A. M., Lehman, K. J., Griffin, D. A., Khan, S. Z., Dharia, S. D., Quintana-Gallardo, L., & Rodino-Klapac, L. R. (2022) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2022.02.011 · Cited by 124 · see citing works

Safety of Intradiaphragmatic Delivery of Adeno-Associated Virus-Mediated Alpha-Glucosidase (rAAV1-CMV- <i>hGAA</i> ) Gene Therapy in Children Affected by Pompe Disease

Corti, M., Liberati, C., Smith, B. K., Lawson, L. A., Tuna, I. S., Conlon, T. J., Coleman, K. E., Islam, S., Herzog, R. W., Fuller, D. D., et al. (2017) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2017.146 · Cited by 120 · see citing works

Immune responses to AAV-vectors, the Glybera example from bench to bedside

Ferreira, V., Petry, H., & Salmon, F. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00082 · Cited by 120 · see citing works

Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia b

Mingozzi, F., Chen, Y., Murphy, S. L., Edmonson, S. C., Tai, A., Price, S. D., Metzger, M. E., Zhou, S., Wright, J. F., Donahue, R. E., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.84 · Cited by 112 · see citing works

Enhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity

Bartel, M. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00204 · Cited by 108 · see citing works

Exposure to wild-type AAV drives distinct capsid immunity profiles in humans

Kuranda, K., Jean-Alphonse, P., Leborgne, C., Hardet, R., Collaud, F., Marmier, S., Costa Verdera, H., Ronzitti, G., Veron, P., & Mingozzi, F. (2018) · Journal of Clinical Investigation · doi:10.1172/jci122372 · Cited by 104 · see citing works

Immunology of AAV-Mediated Gene Transfer in the Eye

Willett, K., & Bennett, J. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00261 · Cited by 105 · see citing works

Diverse IgG subclass responses to adeno‐associated virus infection and vector administration

Murphy, S. L., Li, H., Mingozzi, F., Sabatino, D. E., Hui, D. J., Edmonson, S. A., & High, K. A. (2009) · Journal of Medical Virology · doi:10.1002/jmv.21360 · Cited by 101 · see citing works

Capsid-specific removal of circulating antibodies to adeno-associated virus vectors

Bertin, B., Veron, P., Leborgne, C., Deschamps, J.-Y., Moullec, S., Fromes, Y., Collaud, F., Boutin, S., Latournerie, V., van Wittenberghe, L., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-57893-z · Cited by 100 · see citing works

Immune Response Mechanisms against AAV Vectors in Animal Models

Martino, A. T., & Markusic, D. M. (2020) · Molecular Therapy - Methods &amp; Clinical Development · doi:10.1016/j.omtm.2019.12.008 · Cited by 97 · see citing works

Recombinant Adeno-Associated Virus Vectors Induce Functionally Impaired Transgene Product-Specific CD8+ T Cells in Mice

Lin, S.-W., Hensley, S. E., Tatsis, N., Lasaro, M. O., & Ertl, H. C. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33138 · Cited by 88 · see citing works

Humoral and Cellular Capsid-Specific Immune Responses to Adeno-Associated Virus Type 1 in Randomized Healthy Donors

Veron, P., Leborgne, C., Monteilhet, V., Boutin, S., Martin, S., Moullier, P., & Masurier, C. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200620 · Cited by 88 · see citing works

Age-Related Seroprevalence of Antibodies Against AAV-LK03 in a UK Population Cohort

Perocheau, D. P., Cunningham, S. C., Lee, J., Antinao Diaz, J., Waddington, S. N., Gilmour, K., Eaglestone, S., Lisowski, L., Thrasher, A. J., Alexander, I. E., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.098 · Cited by 81 · see citing works

The impact of pre-existing immunity on the non-clinical pharmacodynamics of AAV5-based gene therapy

Long, B. R., Sandza, K., Holcomb, J., Crockett, L., Hayes, G. M., Arens, J., Fonck, C., Tsuruda, L. S., Schweighardt, B., O’Neill, C. A., et al. (2019) · Molecular Therapy - Methods &amp; Clinical Development · doi:10.1016/j.omtm.2019.03.006 · Cited by 75 · see citing works

Transient and Intensive Pharmacological Immunosuppression Fails to Improve AAV-based Liver Gene Transfer in Non-Human Primates

Unzu, C., Hervás-Stubbs, S., Sampedro, A., Mauleón, I., Mancheño, U., Alfaro, C., de Salamanca, R. E., Benito, A., Beattie, S. G., Petry, H., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-122 · Cited by 69 · see citing works

Strategies to circumvent humoral immunity to adeno-associated viral vectors

Tse, L. V., Moller-Tank, S., & Asokan, A. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1035645 · Cited by 61 · see citing works

Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies

Chu, W. S., & Ng, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658038 · Cited by 59 · see citing works

Immunoadsorption enables successful rAAV5-mediated repeated hepatic gene delivery in nonhuman primates

Salas, D., Kwikkers, K. L., Zabaleta, N., Bazo, A., Petry, H., van Deventer, S. J., Aseguinolaza, G. G., & Ferreira, V. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000380 · Cited by 59 · see citing works

Subretinal delivery of adeno-associated virus serotype 2 results in minimal immune responses that allow repeat vector administration in immunocompetent mice

Barker, S. E., Broderick, C. A., Robbie, S. J., Duran, Y., Natkunarajah, M., Buch, P., Balaggan, K. S., MacLaren, R. E., Bainbridge, J. W. B., Smith, A. J., et al. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1327 · Cited by 59 · see citing works

MyD88 Signaling in B Cells Regulates the Production of Th1-dependent Antibodies to AAV

Sudres, M., Ciré, S., Vasseur, V., Brault, L., Da Rocha, S., Boisgérault, F., Le Bec, C., Gross, D. A., Blouin, V., Ryffel, B., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.101 · Cited by 59 · see citing works

Recommendations for the Development of Cell-Based Anti-Viral Vector Neutralizing Antibody Assays

Gorovits, B., Fiscella, M., Havert, M., Koren, E., Long, B., Milton, M., & Purushothama, S. (2020) · The AAPS Journal · doi:10.1208/s12248-019-0403-1 · Cited by 57 · see citing works

A versatile toolkit for overcoming AAV immunity

Li, X., Wei, X., Lin, J., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.991832 · Cited by 57 · see citing works

Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes

Hui, D. J., Basner-Tschakarjan, E., Chen, Y., Davidson, R. J., Buchlis, G., Yazicioglu, M., Pien, G. C., Finn, J. D., Haurigot, V., Tai, A., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.166 · Cited by 47 · see citing works

ImmTOR nanoparticles enhance AAV transgene expression after initial and repeat dosing in a mouse model of methylmalonic acidemia

Ilyinskii, P. O., Michaud, A. M., Rizzo, G. L., Roy, C. J., Leung, S. S., Elkins, S. L., Capela, T., Chowdhury, A., Li, L., Chandler, R. J., et al. (2021) · Molecular Therapy - Methods &amp; Clinical Development · doi:10.1016/j.omtm.2021.06.015 · Cited by 39 · see citing works

Complement Activation by Adeno-Associated Virus-Neutralizing Antibody Complexes

West, C., Federspiel, J. D., Rogers, K., Khatri, A., Rao-Dayton, S., Ocana, M. F., Lim, S., D'Antona, A. M., Casinghino, S., & Somanathan, S. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.018 · Cited by 39 · see citing works

Mycophenolate mofetil impairs transduction of single-stranded adeno-associated viral vectors

Montenegro-Miranda, P. S., Bloemendaal, L. T., Kunne, C., de Waart, D. R., & Bosma, P. J. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.222 · Cited by 35 · see citing works

Obstacles and future of gene therapy for hemophilia

Arruda, V. R., & Samelson-Jones, B. J. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1069179 · Cited by 33 · see citing works

Ocular Inflammation and Treatment Emergent Adverse Events in Retinal Gene Therapy

Mehta, N., Robbins, D. A., & Yiu, G. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000366 · Cited by 33 · see citing works

Induction of T-Cell Infiltration and Programmed Death Ligand 2 Expression by Adeno-Associated Virus in Rhesus Macaque Skeletal Muscle and Modulation by Prednisone

Cramer, M. L., Shao, G., Rodino-Klapac, L. R., Chicoine, L. G., & Martin, P. T. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.113 · Cited by 22 · see citing works

Superior human hepatocyte transduction with adeno-associated virus vector serotype 7

Shao, W., Pei, X., Cui, C., Askew, C., Dobbins, A., Chen, X., Abajas, Y. L., Gerber, D. A., Samulski, R. J., Nichols, T. C., et al. (2019) · Gene Therapy · doi:10.1038/s41434-019-0104-5 · Cited by 22 · see citing works

AAV2-VEGF-B gene therapy failed to induce angiogenesis in ischemic porcine myocardium due to inflammatory responses

Korpela, H., Lampela, J., Airaksinen, J., Järveläinen, N., Siimes, S., Valli, K., Nieminen, T., Turunen, M., Grönman, M., Saraste, A., et al. (2022) · Gene Therapy · doi:10.1038/s41434-022-00322-9 · Cited by 22 · see citing works

Directed Evolution of AAV Targeting Primate Retina by Intravitreal Injection Identifies R100, a Variant Demonstrating Robust Gene Delivery and Therapeutic Efficacy in Non-Human Primates

Kotterman, M., Beliakoff, G., Croze, R., Vazin, T., Schmitt, C., Szymanski, P., Leong, M., Quezada, M., Holt, J., Barglow, K., et al. (2021) · doi:10.1101/2021.06.24.449775 · Cited by 20 · see citing works

Prevalence of Anti-Adeno-Associated Virus Serotype 9 Antibodies in Adult Patients with Spinal Muscular Atrophy

Stolte, B., Schreiber-Katz, O., Günther, R., Wurster, C. D., Petri, S., Osmanovic, A., Freigang, M., Uzelac, Z., Leo, M., von Velsen, O., et al. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.054 · Cited by 15 · see citing works

MSD-based assays facilitate a rapid and quantitative serostatus profiling for the presence of anti-AAV antibodies

Haar, J., Blazevic, D., Strobel, B., Kreuz, S., & Michelfelder, S. (2022) · Molecular Therapy - Methods &amp; Clinical Development · doi:10.1016/j.omtm.2022.04.008 · Cited by 11 · see citing works

Prevention and inhibition of adverse humoral immune response to gene therapy mediated by adeno-associated virus (AAV) vector

Meliani, A. (2026) · doi:10.70675/83ee599czfe90z44e6za201z0938409e1748

Immunosuppression after pediatric liver transplant: The parents’ perspective

Batsis, I. D., Bucuvalas, J. C., Eisenberg, E., Lau, J., Squires, J. E., Feng, S., & Perito, E. R. (2023) · Clinical Transplantation · doi:10.1111/ctr.14931 · Cited by 4 · see citing works

General Principle of Immunosuppression

Blisard, D. (2013) · Oxford University Press eBooks · doi:10.1093/med/9780199768899.003.0008

Current Use of Immunosuppression in Liver Transplantation

Adjei, M. A., & Kim, I. K. (2023) · Surgical Clinics of North America · doi:10.1016/j.suc.2023.08.004 · Cited by 3 · see citing works

Gene Therapy Progress and Prospects: Gene therapy in organ transplantation

Bagley, J., & Iacomini, J. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302020 · Cited by 52 · see citing works

Advance in treatment of rheumatoid arthritis.

Lu, Z. (2010) · Zhongguo redai yixue